pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,640 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1789Endpoints1393Fierce Biotech712BioSpace702BioPharma Dive526raps234onclive165fda recalls113
therapy area
allOncology12362Rare Disease3231Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • AI-driven admin tech continues to dominate health-tech funding landscape
    The article notes that administrative technology remains the leading segment within health‑tech investment. Startups that apply artificial intelligence to automate routine tasks such as patient fol…
    Endpoints · 6mo agoPositive↗ source
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    STAT · 6mo agoDealNeutral↗ source
← prev
page 143 of 146
next →
fda medwatch111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1064
Pain778
Endocrinology & Metabolism777
Nephrology762
Eli Lilly announces second partnership this year to advance recombinase-based gene editing
Eli Lilly has entered a second partnership this year aimed at developing recombinase-based gene‑editing technologies. The collaboration follows earlier efforts to explore enzymes that can precisely…
Endpoints · 6mo agoDealPositive↗ source
  • GOP Medicaid work requirements face data gap as states not required to report implementation
    The 2025 tax cut law added work requirements to Medicaid, prompting a sharp partisan split. Democrats warn the new rules will create red tape and lead to loss of coverage, while Republicans argue t…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Health system CEOs face Congress on affordability, hearing shifts blame to opposing party's policies
    The House Ways and Means Committee held a hearing to examine the drivers of rising health‑care costs, calling CEOs of several large health systems to testify. CEOs from HCA Healthcare, CommonSpiri…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Experts warn brain-health initiatives overlook mental illness
    The authors – a professor at Oxford and Yale, the dean of Mount Sinai’s medical school, and a former U.S. congressman – argue that the surge in funding for neuroscience is being directed mainly tow…
    STAT · 6mo agoNegative↗ source
  • Former NIAID adviser David Morens indicted for hiding emails and falsifying records
    David Morens, a former senior adviser at the National Institute of Allergy and Infectious Diseases, was indicted on Tuesday for allegedly concealing emails and providing false responses to Freedom…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Rocket Pharmaceuticals sells pediatric disease priority review voucher for $180 million; Oruka eyes $500 million offering
    Rocket Pharmaceuticals, a New Jersey gene-therapy company, sold its priority review voucher for a rare pediatric disease to an undisclosed buyer for $180 million. The voucher was earned after the…
    Endpoints · 6mo agoDealNeutral↗ source
  • Google’s clinical director discusses AI challenges in health care in STAT Health Tech newsletter
    STAT Health Tech newsletter featured an interview with Google’s clinical director, focusing on the practical challenges of deploying artificial intelligence in health care settings. The discussion…
    STAT · 6mo agoNeutral↗ source
  • Devoted Health reports first revenue decline in 2025 amid Medicare Advantage turbulence
    Devoted Health, a startup offering Medicare Advantage plans, saw its revenue and membership drop in 2025, marking the first decline since it began offering plans seven years ago. The downturn refl…
    Endpoints · 6mo agoNegative↗ source
  • New hepatitis B vaccine guidance prompts analysis of public trust and policy impacts
    The Morning Rounds newsletter examines how the latest recommendations for a hepatitis B vaccine could affect public health outcomes. It highlights recent surveys that show varying levels of confid…
    STAT · 6mo agoNeutral↗ source
  • EPA proposes first rule to flag microplastics and pharmaceuticals in drinking water, alongside $144 million ARPA-H study program
    The Environmental Protection Agency announced a proposed rule that would formally label microplastics and pharmaceutical residues in drinking water as contaminants that merit federal study and trac…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Adaptyv Bio shares results from its latest AI-driven protein design contest
    Adaptyv Bio, a biotech firm focused on protein engineering, released the outcomes of its newest competition that tests how well artificial‑intelligence models can create novel proteins. The challe…
    Endpoints · 6mo agoNeutral↗ source
  • Google AI clinical director says chatbot can serve as bridge for mental health crises
    Google’s clinical director, Megan Jones Bell, told STAT that the company is working to make its Gemini chatbot a helpful resource for users experiencing mental health crises. She emphasized that th…
    STAT · 6mo agoPositive↗ source
  • STAT seeks reader input on adopting AP’s “healthcare” spelling
    The Associated Press Stylebook recently announced that the term "healthcare" should be written as a single word, updating its long-standing guidance. STAT, which has used the two-word form "health…
    STAT · 6mo agoNeutral↗ source
  • Intellia's single-dose CRISPR therapy cuts hereditary angioedema attacks in Phase 3 trial
    Intellia Therapeutics reported that its gene-editing candidate lonvo-z produced a dramatic reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 study. The single-dose…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Intellia's in-body CRISPR therapy achieves first Phase 3 success
    Intellia announced that its experimental in vivo CRISPR gene‑editing therapy has completed a Phase 3 trial with positive results. This is the first instance of a CRISPR‑based treatment delivered d…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trial
    Intellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Sun Pharma to acquire Organon for $11.75 billion in all-cash deal
    Indian pharmaceutical company Sun Pharma announced it will purchase Organon, a company focused on women's health and biosimilars that was spun out of Merck in 2021. The transaction is an all-cash…
    Endpoints · 6mo agoDealPositive↗ source
  • Intellia reports positive Phase 3 readout for CRISPR gene-editing therapy in hereditary angioedema
    Intellia Therapeutics announced that its CRISPR-based therapy achieved a successful readout in a Phase 3 trial for hereditary angioedema, a rare condition marked by sudden, potentially dangerous sw…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warn
    A new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer deal
    Eli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…
    Endpoints · 6mo agoDealPositive↗ source
  • Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock drop
    Compass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success. The additi…
    Endpoints · 6mo agoNegative readoutNegative↗ source
  • Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trial
    Oruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Supreme Court split on blocking thousands of Roundup cancer lawsuits
    The Supreme Court heard arguments on Monday about whether to block thousands of lawsuits claiming the weedkiller Roundup caused cancer, and the justices appeared divided. The dispute follows a wav…
    STAT · 6mo agoRegulatoryNegative↗ source